

Applicants: Sharon Cohen-Vered, et al.  
Serial No.: 10/758,572  
Filed : January 14, 2004  
Page : 2 of 20

**Amendments to the Specification**

Please replace the paragraph beginning on page 26, line 19 with the following paragraph:

CAPTISOL® is a commercially available polyanionic  $\beta$ -cyclodextrin derivative with a sodium sulfonate salt separated from the hydrophobic cavity by a butyl ether spacer group, or sulfobutylether (SBE). CAPTISOL® is the trade name for CyDex Inc.'s hepta-substituted sulfobutylether  $\beta$ -cyclodextrin (SBE7- $\beta$ -CD) preparation ([www.captisol.com](http://www.captisol.com)). The structure of CAPTISOL® allows drug molecules to fit in the hydrophobic cavity, thereby isolating the drug molecule from the aqueous solvent. Because the outer surface of CAPTISOL® is hydrophilic, the solubility of the complexed drug molecule is thereby enhanced. The use of cyclodextrins to enhance the solubility of drug molecules is disclosed in U.S. Patent Nos. 5,134,127 and 5,376,645, the entire contents of which are hereby incorporated by reference.